CapsoVision Q4 Earnings Call Highlights [Yahoo! Finance]
CapsoVision, Inc. (CV)
Company Research
Source: Yahoo! Finance
Q4 patients (12% YoY) and over patients imaged to date, driven by its wire-free 360° capsule and cloud workflow. Pipeline progress includes a submitted 510(k) for an AI-assisted reading module (end of 2025) and the CapsoCam Colon Gen2 pivotal study with over 500–600 enrollees; management plans a Gen2 and AI 510(k) filing in Q3 2026 with potential FDA clearance ~Q1 2027 and a H2 2027 launch, while a CapsoCam UGI pancreatic diagnostic study is expected to start in Q2 2026 to define scoring criteria. Financially, Q4 revenue was $3.9 million (up 13% YoY) with operating expenses of $9.4 million and year-end cash of $10.1 million, and the company completed a $14 million private placement to support commercial expansion, R&D and pipeline advancement. Interested in CapsoVision, Inc.? Here are five stocks we like better. 3 Under-the-Radar Software Stocks Ready to Bounce CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsul
Show less
Read more
Impact Snapshot
Event Time:
CV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CV alerts
High impacting CapsoVision, Inc. news events
Weekly update
A roundup of the hottest topics
CV
News
- CapsoVision (CV) had its price target lowered by Benchmark Co. from $14.00 to $10.00. They now have a "speculative buy" rating on the stock.MarketBeat
- CapsoVision, Inc. reports Q4 results [Seeking Alpha]Seeking Alpha
- CapsoVision Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening [Yahoo! Finance]Yahoo! Finance
- CapsoVision Announces $14 Million Private Placement Financing [Yahoo! Finance]Yahoo! Finance
CV
Earnings
- 3/26/26 - Miss
CV
Sec Filings
- 3/26/26 - Form 3
- 3/26/26 - Form 10-K
- 3/23/26 - Form 4
- CV's page on the SEC website